Laurence Chiche
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Laurence Chiche has a total of 152 co-authors. Here are the top co-authors by number of shared publications:
Christophe Laurent
Department of Hepato-Bilio-Pancreatic Surgery and Liver Transplantation, Haut Lévêque Hospital, CHU de Bordeaux, Bordeaux, France
5 shared publicationsJean-Philippe Adam
Department of Hepato-bilio-pancreatic Surgery and Liver Transplantation, Haut-Levêque Hospital, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France
5 shared publications- Charles Balabaud
Inserm, U1053, Bordeaux University Bordeaux France
4 shared publications - Christophe Cassinotto
Department of Radiology, St-Eloi University Hospital, Montpellier, France
4 shared publications Arthur Marichez
Department of Hepato-bilio-pancreatic Surgery and Liver Transplantation, Haut-Levêque Hospital, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France; Inserm UMR 1312, Bordeaux Institute of Oncology (BRIC), University of Bordeaux, Bordeaux, France
3 shared publications- Christophe Laurent
CHU Bordeaux/Bordeaux University, Chirurgie Hepato-Bilio-Pancreatique, Pessac, France
3 shared publications
Latest Publications
- 1 October 2025
- Published by Elsevier in Clinics and Research in Hepatology and Gastroenterology
- Vol. 49 (9) , 102701
Protecting the fetus during hepatic surgery in pregnancy: the role of cavo-caval bypass
- 1 October 2025
- Published by Elsevier in Clinics and Research in Hepatology and Gastroenterology
- Vol. 49 (9) , 102701
Protecting the fetus during hepatic surgery in pregnancy: the role of cavo-caval bypass
- 14 November 2024
- Published by Springer Nature in Updates in Surgery
- Vol. 77 (1) , 65-75
Liver transplantation: Do not abandon T-tube drainage—a multicentric retrospective study of the ARCHET research group
Biliary complications remain a real issue in liver transplantation (LT). Despite meta-analyses, the anastomosis technique, especially the use of biliary drain as T-Tube drain (TT) or transcystic drain, remains controversial. This study conducted by the ARCHET research group examine the incidence and types of biliary complications (BC) after LT according to the presence or absence of a biliary drain. 1485 patients with LT surgery between 2009 to 2015 in 4 LT centers were included, divided into 3 groups: no drain (ND n = 442), transcystic drain (TCD, n = 169) and TT(n = 874).The T-Tube group includes 3 techniques: transanastomotic, subanastomotic and tunneled retroperitoneal. Fistula and biliary stricture (AS) rates were studied. The risk factors of BC were investigated by multivariate analysis. The BC rate was lower in the TT group (17% TT, 25% TCD, 31% ND, p < 0.05), the complication rate Dindo-Clavien grade ≥ III is higher in the ND group (24% vs. 10% TT p < 0.05). Arterial complication has been found as a risk factor of BC with the multivariate analysis (p < 0.01, OR 1.86 [1.20–2.84]). In addition, the TT decreased by 5 the risk of AS (p < 0.05, OR 0.19 [0.12–0.28]). The fistula rate does not differ regardless of the reconstruction mode. In this study, biliary drain decreases the rate of BC. The findings confirmed the role of T-tube insertion in prevention of AS regardless of the way it is set up.
- 14 November 2024
- Published by Springer Nature in Updates in Surgery
- Vol. 77 (1) , 65-75
Liver transplantation: Do not abandon T-tube drainage—a multicentric retrospective study of the ARCHET research group
Biliary complications remain a real issue in liver transplantation (LT). Despite meta-analyses, the anastomosis technique, especially the use of biliary drain as T-Tube drain (TT) or transcystic drain, remains controversial. This study conducted by the ARCHET research group examine the incidence and types of biliary complications (BC) after LT according to the presence or absence of a biliary drain. 1485 patients with LT surgery between 2009 to 2015 in 4 LT centers were included, divided into 3 groups: no drain (ND n = 442), transcystic drain (TCD, n = 169) and TT(n = 874).The T-Tube group includes 3 techniques: transanastomotic, subanastomotic and tunneled retroperitoneal. Fistula and biliary stricture (AS) rates were studied. The risk factors of BC were investigated by multivariate analysis. The BC rate was lower in the TT group (17% TT, 25% TCD, 31% ND, p < 0.05), the complication rate Dindo-Clavien grade ≥ III is higher in the ND group (24% vs. 10% TT p < 0.05). Arterial complication has been found as a risk factor of BC with the multivariate analysis (p < 0.01, OR 1.86 [1.20–2.84]). In addition, the TT decreased by 5 the risk of AS (p < 0.05, OR 0.19 [0.12–0.28]). The fistula rate does not differ regardless of the reconstruction mode. In this study, biliary drain decreases the rate of BC. The findings confirmed the role of T-tube insertion in prevention of AS regardless of the way it is set up.
- 23 July 2024
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 280 (5) , 693-695
The Human Factor in a New Surgical Era
An abstract is unavailable. This article is available as a PDF only.
- 23 July 2024
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 280 (5) , 693-695
The Human Factor in a New Surgical Era
An abstract is unavailable. This article is available as a PDF only.
- Open Access
- 1 October 2023
- Published by AME Publishing Company in HepatoBiliary Surgery and Nutrition
- Vol. 12 (5) , 740-742
Modified Appleby: experience improves short-term results, but is it enough?
Modified Appleby: experience improves short-term results, but is it enough?
- 1 October 2023
- Published by AME Publishing Company in HepatoBiliary Surgery and Nutrition
- Vol. 12 (5) , 740-742
Open AccessModified Appleby: experience improves short-term results, but is it enough?
Modified Appleby: experience improves short-term results, but is it enough?
- 27 February 2023
- Published by Springer Nature in Langenbeck's Archives of Surgery
- Vol. 408 (1) , 1-10
Hepaticojejunostomy for bile duct injury: state of the art
Background Hepaticojejunostomy (HJ) is the gold standard procedure for the reconstruction of the bile duct in many benign and malignant situations. One of the major situation is the bile duct injury (BDI) after cholecystectomy, either for early or late repair. This procedure presents some specificities associated to a debated management of BDI. Purpose This article provides a state-of-the-art of the hepaticojejunostomy procedure focusing on bile duct injury including its indications and outcomes Conclusion Performed at the right moment and respecting the technical rules, HJ provides a restoration of the biliary patency in the long term of 80 to 90%. It is the main surgical technique to repair BDI. Complications and failure of this procedure can be difficult to manage. That is why the primary repair requires an appropriate multidisciplinary approach associated with an expert high quality surgical technique.
- 27 February 2023
- Published by Springer Nature in Langenbeck's Archives of Surgery
- Vol. 408 (1) , 1-10
Hepaticojejunostomy for bile duct injury: state of the art
Background Hepaticojejunostomy (HJ) is the gold standard procedure for the reconstruction of the bile duct in many benign and malignant situations. One of the major situation is the bile duct injury (BDI) after cholecystectomy, either for early or late repair. This procedure presents some specificities associated to a debated management of BDI. Purpose This article provides a state-of-the-art of the hepaticojejunostomy procedure focusing on bile duct injury including its indications and outcomes Conclusion Performed at the right moment and respecting the technical rules, HJ provides a restoration of the biliary patency in the long term of 80 to 90%. It is the main surgical technique to repair BDI. Complications and failure of this procedure can be difficult to manage. That is why the primary repair requires an appropriate multidisciplinary approach associated with an expert high quality surgical technique.
- Open Access
- 1 October 2022
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 12 (10) , 1624
The Safety and Efficacy of Hepatic Transarterial Embolization Using Microspheres and Microcoils in Patients with Symptomatic Polycystic Liver Disease
Purpose: We investigated the long-term safety and efficacy of hepatic transarterial embolization (TAE) in patients with symptomatic polycystic liver disease (PLD). Materials and Methods: A total of 26 patients were included, mean age of 52.3 years (range: 33–78 years), undergoing 32 TAE procedures between January 2012 and December 2019 were included in this retrospective study. Distal embolization of the segmental hepatic artery was performed with 300–500 µm embolic microspheres associated with proximal embolization using microcoils. The primary endpoint was clinical efficacy, defined by an improvement in health-related quality of life using a modified Short Form-36 Health Survey and improvement in symptoms (digestive or respiratory symptoms and chronic abdominal pain), without invasive therapy during the follow-up period. Secondary endpoints were a decrease in total liver volume and treated liver volume and complications. Results: Hepatic embolization was performed successfully in 30 of 32 procedures with no major adverse events. Clinical efficacy was 73% (19/26). The mean reduction in hepatic volume was −12.6% at 3 months and −27.8% at the last follow-up 51 ± 15.2 months after TAE (range: 30–81 months; both ps < 0.01). The mean visual analog scale pain score was 5.4 ± 2.8 before TAE and decreased to 2.7 ± 1.9 after treatment. Three patients had minor adverse events, and one patient had an adverse event of moderate severity. Conclusion: Hepatic embolization using microspheres and microcoils is a safe and effective treatment for PLD that improves symptoms and reduces the volume of hepatic cysts.
- 1 October 2022
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 12 (10) , 1624
Open AccessThe Safety and Efficacy of Hepatic Transarterial Embolization Using Microspheres and Microcoils in Patients with Symptomatic Polycystic Liver Disease
Purpose: We investigated the long-term safety and efficacy of hepatic transarterial embolization (TAE) in patients with symptomatic polycystic liver disease (PLD). Materials and Methods: A total of 26 patients were included, mean age of 52.3 years (range: 33–78 years), undergoing 32 TAE procedures between January 2012 and December 2019 were included in this retrospective study. Distal embolization of the segmental hepatic artery was performed with 300–500 µm embolic microspheres associated with proximal embolization using microcoils. The primary endpoint was clinical efficacy, defined by an improvement in health-related quality of life using a modified Short Form-36 Health Survey and improvement in symptoms (digestive or respiratory symptoms and chronic abdominal pain), without invasive therapy during the follow-up period. Secondary endpoints were a decrease in total liver volume and treated liver volume and complications. Results: Hepatic embolization was performed successfully in 30 of 32 procedures with no major adverse events. Clinical efficacy was 73% (19/26). The mean reduction in hepatic volume was −12.6% at 3 months and −27.8% at the last follow-up 51 ± 15.2 months after TAE (range: 30–81 months; both ps < 0.01). The mean visual analog scale pain score was 5.4 ± 2.8 before TAE and decreased to 2.7 ± 1.9 after treatment. Three patients had minor adverse events, and one patient had an adverse event of moderate severity. Conclusion: Hepatic embolization using microspheres and microcoils is a safe and effective treatment for PLD that improves symptoms and reduces the volume of hepatic cysts.
- 29 July 2021
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 274 (5) , 843-850
Hepatocellular Adenoma Risk Factors of Hemorrhage: Size Is Not the Only Concern!
Objective: Our aim was to determine independent risk factors of clinical bleeding of hepatocellular adenoma (HCA) to define a better management strategy. Summary Background Data: HCA is a rare benign liver tumor with severe complications: malignant transformation that is rare (5%–8%) and more often, hemorrhage (20%–27%). To date, only size > 5 cm and histological subtype (possibly sonic hedgehog) are associated with bleeding, but these criteria are not clearly established. Methods: We retrospectively collected data from a cohort of 268 patients with HCA managed in our tertiary center, from 1984 to 2020 and focused on clinical bleeding. Hemorrhage was considered severe when it required intensive care and moderate when bleeding symptoms required a hospitalization. We included 261 patients, of whom 130 (49.8%) had multiple HCAs or liver adenomatosis. All surgical specimen and liver biopsy were reviewed by an experienced liver pathologist and reclassified in the light of the current immunohistochemistry. Mean duration of follow-up was 93.3 months (range 1–363). We analyzed type, frequency, consequences of bleeding, and risk factors among clinical data and HCA characteristics. Results: Eighty-three HCA (31.8%) were hemorrhagic. There were 4 pregnant women with 1 newborn death. One patient died before treatment. Surgery was performed in 78 (94.0%) patients. Mortality was nil and severe complications occurred in 11.5%. Multivariate analysis identified size (OR 1.02 [1.01–1.02], P < 0.001), shHCA (OR 21.02 [5.05–87.52], P < 0.001), b-catenin mutation on exon 7/8 (OR 6.47 [1.78–23.55], P = 0.0046), chronic alcohol consumption (OR 9.16 [2.47–34.01], P < 0.001) as independent risk factors of clinical bleeding. Conclusions: This series, focused on the hemorrhagic risk of HCA, shows that size, but rather more molecular subtype is determinant in the natural history of HCA.
- 29 July 2021
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 274 (5) , 843-850
Hepatocellular Adenoma Risk Factors of Hemorrhage: Size Is Not the Only Concern!
Objective: Our aim was to determine independent risk factors of clinical bleeding of hepatocellular adenoma (HCA) to define a better management strategy. Summary Background Data: HCA is a rare benign liver tumor with severe complications: malignant transformation that is rare (5%–8%) and more often, hemorrhage (20%–27%). To date, only size > 5 cm and histological subtype (possibly sonic hedgehog) are associated with bleeding, but these criteria are not clearly established. Methods: We retrospectively collected data from a cohort of 268 patients with HCA managed in our tertiary center, from 1984 to 2020 and focused on clinical bleeding. Hemorrhage was considered severe when it required intensive care and moderate when bleeding symptoms required a hospitalization. We included 261 patients, of whom 130 (49.8%) had multiple HCAs or liver adenomatosis. All surgical specimen and liver biopsy were reviewed by an experienced liver pathologist and reclassified in the light of the current immunohistochemistry. Mean duration of follow-up was 93.3 months (range 1–363). We analyzed type, frequency, consequences of bleeding, and risk factors among clinical data and HCA characteristics. Results: Eighty-three HCA (31.8%) were hemorrhagic. There were 4 pregnant women with 1 newborn death. One patient died before treatment. Surgery was performed in 78 (94.0%) patients. Mortality was nil and severe complications occurred in 11.5%. Multivariate analysis identified size (OR 1.02 [1.01–1.02], P < 0.001), shHCA (OR 21.02 [5.05–87.52], P < 0.001), b-catenin mutation on exon 7/8 (OR 6.47 [1.78–23.55], P = 0.0046), chronic alcohol consumption (OR 9.16 [2.47–34.01], P < 0.001) as independent risk factors of clinical bleeding. Conclusions: This series, focused on the hemorrhagic risk of HCA, shows that size, but rather more molecular subtype is determinant in the natural history of HCA.
- 1 July 2020
- Published by Elsevier in Gastroenterology
- Vol. 159 (1) , 42-44
An Intraductal Papillary Mucinous Neoplasm With Portal Thrombosis
- 1 July 2020
- Published by Elsevier in Gastroenterology
- Vol. 159 (1) , 42-44
An Intraductal Papillary Mucinous Neoplasm With Portal Thrombosis